These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29705998)

  • 41. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Misunderstandings.
    Feldman SR
    J Dermatolog Treat; 2007; 18(1):4. PubMed ID: 17365258
    [No Abstract]   [Full Text] [Related]  

  • 44. [Psoriasis updates].
    Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
    [No Abstract]   [Full Text] [Related]  

  • 45. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
    Gaspari AA; Tyring S
    Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Intra-ungual linear opacities in psoriasis. Apropos of 10 cases].
    de Graciansky P; Larrègue M; Katz M
    Ann Dermatol Syphiligr (Paris); 1975; 102(2):121-8. PubMed ID: 1231624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest.
    Lamberg L
    JAMA; 2003 Jun; 289(21):2779-80, 2783. PubMed ID: 12783895
    [No Abstract]   [Full Text] [Related]  

  • 49. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 51. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
    Nijsten T; Spuls PI
    Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
    [No Abstract]   [Full Text] [Related]  

  • 52. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 53. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First case of secukinumab successful therapy in a very elderly psoriatic patient.
    Ricceri F; Pescitelli L; Lazzeri L; Di Cesare A; Prignano F
    Dermatol Ther; 2018 Sep; 31(5):e12668. PubMed ID: 30209856
    [No Abstract]   [Full Text] [Related]  

  • 59. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.